Jefferies Financial Group set a $60.00 target price on Pacira Biosciences (NASDAQ:PCRX) in a research report report published on Tuesday morning, TipRanks reports. The brokerage currently has a buy rating on the stock. Jefferies Financial Group also issued estimates for Pacira Biosciences’ Q3 2019 earnings at $0.21 EPS, Q4 2019 earnings at $0.39 EPS, FY2019 earnings at $0.83 EPS and FY2020 earnings at $1.75 EPS.
Several other equities research analysts have also issued reports on the stock. Stifel Nicolaus set a $42.00 price target on shares of Pacira Biosciences and gave the stock a hold rating in a research note on Friday, August 9th. Barclays initiated coverage on shares of Pacira Biosciences in a research note on Tuesday, June 11th. They set an overweight rating and a $52.00 price target for the company. Zacks Investment Research upgraded shares of Pacira Biosciences from a sell rating to a hold rating and set a $47.00 price target for the company in a research note on Friday, August 2nd. BMO Capital Markets decreased their price target on shares of Pacira Biosciences from $46.00 to $43.00 and set a market perform rating for the company in a research note on Friday, August 9th. Finally, BidaskClub lowered shares of Pacira Biosciences from a hold rating to a sell rating in a research note on Thursday, October 3rd. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the stock. Pacira Biosciences presently has a consensus rating of Hold and a consensus price target of $55.00.
Shares of Pacira Biosciences stock traded up $0.92 during mid-day trading on Tuesday, hitting $37.69. 447,930 shares of the stock were exchanged, compared to its average volume of 646,682. Pacira Biosciences has a 12 month low of $34.64 and a 12 month high of $55.00. The company has a 50-day simple moving average of $37.57 and a 200 day simple moving average of $40.87. The company has a debt-to-equity ratio of 0.99, a quick ratio of 4.12 and a current ratio of 4.75. The company has a market capitalization of $1.53 billion, a P/E ratio of 129.97, a P/E/G ratio of 1.74 and a beta of 1.11.
Pacira Biosciences (NASDAQ:PCRX) last posted its earnings results on Thursday, August 8th. The company reported $0.41 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.14 by $0.27. Pacira Biosciences had a net margin of 2.04% and a return on equity of 8.62%. The firm had revenue of $102.60 million for the quarter, compared to analysts’ expectations of $99.92 million. During the same quarter last year, the firm earned $0.24 EPS. The company’s quarterly revenue was up 22.0% compared to the same quarter last year. Analysts predict that Pacira Biosciences will post 0.64 EPS for the current year.
In related news, insider Kristen Marie Williams sold 6,252 shares of Pacira Biosciences stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $39.49, for a total value of $246,891.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO David M. Stack sold 12,849 shares of Pacira Biosciences stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $39.15, for a total transaction of $503,038.35. The disclosure for this sale can be found here. Company insiders own 5.80% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Smith Asset Management Group LP grew its stake in Pacira Biosciences by 181.2% in the 2nd quarter. Smith Asset Management Group LP now owns 27,131 shares of the company’s stock valued at $1,180,000 after buying an additional 17,481 shares in the last quarter. DekaBank Deutsche Girozentrale grew its stake in Pacira Biosciences by 156.1% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 52,630 shares of the company’s stock valued at $2,313,000 after buying an additional 32,082 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Pacira Biosciences by 414.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,436 shares of the company’s stock valued at $63,000 after buying an additional 1,157 shares in the last quarter. Spyglass Capital Management LLC grew its stake in Pacira Biosciences by 59.3% in the 2nd quarter. Spyglass Capital Management LLC now owns 379,609 shares of the company’s stock valued at $16,509,000 after buying an additional 141,282 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Pacira Biosciences by 1,036.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 158,013 shares of the company’s stock valued at $6,942,000 after buying an additional 144,108 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.
Pacira Biosciences Company Profile
Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.
Recommended Story: What is the CBOE Russell 2000® Volatility Index?
Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.